Biotech Traders thread
by alanh | April 16, 2015 4:35 pm
Many of the comments on the main bio threads are about day to day trading activity. This thread has been created so as to cut down the quantity of posts on the main bio threads, plus give traders their own space to bat stuff around. There is no thread leader as the thoughts are momentary. So it works like a ticker tape as do the SP’s.
Enjoy
PS Anyone use Candlesticks?
Source URL: https://www.stockgumshoe.com/2015/04/microblog-biotech-traders-thread/
kerx- http://globenewswire.com/news-release/2015/09/24/770644/10150376/en/Keryx-Receives-European-Approval-for-Fexeric-R-ferric-citrate-coordination-complex-for-the-Treatment-of-Hyperphosphatemia-in-Adults-With-Chronic-Kidney-Disease.html
ARWR- Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study
– Single-dose Reductions in HBeAg of up to 98% (1.7 log) also achieved
– Multi-dose studies in chimpanzees showed peak reduction in HBsAg of up to 99.8% (2.7 log)
– Company hosts an analyst and investor day today to discuss results
PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is hosting an analyst day today in New York, with a presentation starting at 11:00 a.m. EDT to discuss top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection. Additionally, the company will discuss findings from a study of 9 chimpanzees that have been treated monthly with ARC-520 for between 6 and 11 months with a background therapy of nucleotide/nucleoside analog inhibitors (NUCs) tenofovir and/or entecavir.
Key findings:
Arrowhead’s proprietary DPC™ platform can effectively and consistently knock down target genes in humans
HBV E-antigen positive (HBeAg-positive) patients on a background of chronic entecavir receiving a 4 mg/kg single-dose of ARC-520 showed a mean maximal 92% (1.2 log) reduction in circulating HBeAg and a best reduction of 98% (1.7 log). Similar mean maximal reductions were also demonstrated in HBV core-related antigen (HBcrAg) from both HBeAg-negative and -positive patients. ARC-520 is designed to silence all gene products expressed by HBV cccDNA, so this data suggests that it may be substantially disrupting additional viral functions.
ARC-520 achieves significant HBV s-Antigen (HBsAg) reductions in humans, particularly in treatment naïve, HBeAg-positive patients
In a cohort of NUC-naïve, HBeAg-positive patients, best peak HBsAg reduction has been 99% (1.9 log) and the mean maximum HBsAg reduction has been 1.05 log through 15 days post ARC-520 treatment. This open-label cohort is fully enrolled; data collection is ongoing and will be continued through Day 85 post ARC-520 treatment. These reductions are substantially higher than results from NUC treatment-experienced cohorts.
Arrowhead identifies a large target HBV population for ARC-520 and describes a new paradigm for the HBV lifecycle
Arrowhead’s long-term chimp study and findings from the clinical study suggest that HBV cccDNA decreases during the HBV lifecycle, especially with the transition from HBeAg-positive to -negative. HBV DNA integrated into host DNA appears to maintain significant HBsAg production as cccDNA declines. This process is accelerated with NUC treatment. ARC-520 specifically targets cccDNA, and NUC-naïve HBeAg-positive patients are expected to be richest in cccDNA. It is estimated in the U.S. that 95% of people chronically infected with HBV are currently NUC-naïve and at least 50% of them are likely to be HBeAg-positive. While it is unknown what impact ARC-520’s broad based effects on HBV biology will have on the sero-clearance process in any of the HBV subgroups, the effect on HBsAg in NUC-naïve HBeAg-positive patients makes this group especially attractive to study and a key focus for multi-dose studies going forward.
ARC-520 induces deep HBsAg reduction in chronically HBV infected chimps and 1 of 4 HBeAg-positive chimps demonstrated signs of immune reactivation during therapy
9 chimps were first suppressed with NUCs and then treated with 6 – 11 monthly doses of ARC-520. 4 HBeAg-positive chimps demonstrated 99% (2 log) mean peak reduction in HBsAg, and 1 of the 4 experienced signs of immune reactivation during therapy; 4 HBeAg-negative chimps demonstrated 81% (0.7 log) mean peak reduction in HBsAg; and 1 chimp transitioning from HBeAg-positive to HBeAg-negative demonstrated peak HBsAg reduction of 87% (0.9 log).
ARC-520 has been well tolerated
84 humans have received ARC-520 and to date no adverse events have been rated as serious or severe, no discontinuations have occurred due to an adverse event, and no laboratory results have indicated any end organ toxicity. Additionally, 9 chimps received 6-11 monthly doses of ARC-520 and no safety signals were detected in any chimp.
Arrowhead expands its HBV portfolio by nominating an additional clinical candidate that is complementary to ARC-520
ARC-520 will continue development including focus on the significant market of e-antigen positive treatment-naïve chronic HBV patients. ARC-521 is being developed to target cccDNA and also, integrated DNA, which appears to be a more significant producer of HBsAg in patients who have been treated with NUCs or who are e-antigen negative. In HBeAg-negative chimps predicted to have higher levels of integrated DNA, administration of the integrant-targeted siRNA in ARC-521 led to 99% (2 logs) of additional HBsAg reduction. The Company expects to file an IND or equivalent for ARC-521 by mid-2016.
Quotes:
Christopher Anzalone, Ph.D., president and CEO of Arrowhead, said, “These are exciting data that represent a significant leap forward for our DPC™ platform, ARC-520, and the HBV field. We have achieved the highest knockdown ever reported in humans with RNAi and a safety profile that continues to be excellent. We are optimistic that this will ultimately translate into powerful clinical outcomes for ARC-520 and follow-on candidates against multiple indications.”
Robert Gish, M.D., clinical professor of medicine (consultant) at Stanford Hospital and Medical Center, said, “These animal and single-dose human studies with ARC-520 in chronic hepatitis B infected individuals provide compelling evidence about a multi-pronged antiviral effect that will accelerate new studies with multiple doses and combination therapy to move forward.”
Robert Lanford, Ph.D., director at the Southwest National Primate Research Center, said, “I have been extremely impressed by the potency of ARC-520 and its ability to reduce multiple viral proteins. The results from the study in chimpanzees have revealed some important new insights about HBV biology and have introduced new ideas about effective ways to intervene in the HBV lifecycle.”
Oh yes. ARWR. Up 22% pre market. <3
Noci
ABUS- Watch on ARWR news per S Manian
ARWR- per Bio Boy Scout Multiple 45+ PT anticipated and Major T/O tgt LONG ZKSS, ARWR Best2ALL-Ben
Benzinga’s Top #PreMarket Gainers
8:08 am ET September 24, 2015 (Benzinga) Print
Conatus Pharmaceuticals Inc (NASDAQ: CNAT) shares rose 25.44 percent to $7.20 in pre-market trading after the company reported top-line results from Multicenter Phase 2 Portal Hypertension clinical trial in patients with liver cirrhosis.
Arrowhead Research Corp (NASDAQ: ARWR) shares rose 22.55 percent to $8.26 in pre-market trading following announcement of results of ARC-520 Hep B study.
Keryx Biopharmaceuticals (NASDAQ: KERX) shares climbed 19.64 percent to $4.69 in pre-market trading following announcement of the EU approval for Fexericx for the treatment of hyperphosphatemia in adults with chronic kidney disease.
CPXX- Celator(R) Pharmaceuticals Announces Positive Results from R&D Programs
8:00 am ET September 24, 2015 (PR Newswire) Print
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, announced their successful R&D efforts to apply the CombiPlex(R) technology platform to optimize the efficacy of anticancer drug combinations incorporating molecularly targeted agents (MTAs).
CombiPlex is Celator’s proprietary technology that aims to address several of the fundamental shortcomings of conventional combination regimens, as well as the inherent challenges in combination drug development. Celator is applying this technology to create new drug combinations that target pathways associated with tumor cell growth and/or resistance to treatment. Such MTAs are being widely pursued with an increasing focus on combining agents that target multiple cellular pathways in order to improve therapeutic responses.
“While there have been promising signs of activity for certain molecularly targeted agents, it is clear that combinations will be required for optimal efficacy,” said Dr. Joseph Bertino, chief scientific officer at Rutgers Cancer Institute of New Jersey and chairman of Celator’s Scientific Advisory Board. “In addition, many combinations will require simultaneous exposure and attempts to accomplish this to date have often led to toxicity problems.”
CombiPlex is well positioned to address the challenges with the development of combination drug candidates. Nano-scale delivery systems coordinate the pharmacokinetics (PK) of drug combinations after administration so that the optimal ratio of the two drugs is exposed to tumor cells for prolonged times while reducing drug exposure and toxicity to normal tissues.
Recent results from preclinical studies conducted by Celator suggest the technology may significantly improve the therapeutic index of combinations containing MTAs. Celator’s efforts have focused on two combinations: the heat shock protein 90 inhibitor AUY922 combined with docetaxel and the MEK inhibitor selumetinib combined with the Akt inhibitor ipatasertib. In both cases, the drug combinations were stably co-formulated in Celator’s proprietary hydrophobic prodrug nanoparticle delivery systems which provided well-coordinated plasma concentrations over 24 hours that were orders of magnitude higher than observed for the free drug combinations. Free drug combinations refer to the drugs as they are currently administered; individual drugs administered in combination without regard to their ratio dependent interaction. In addition, whereas combined treatment with the free drugs required marked dose reductions due to toxicity, the nanoparticle formulations could be administered at higher doses.
For both combinations, the CombiPlex formulations provided significant improvements in efficacy over the free drugs in human xenograft tumor models including breast, colorectal and ovarian. Furthermore, there was evidence of strong drug ratio-dependent efficacy and in vivo synergy.
Another benefit observed during this research was the versatility and modular nature of the nanoparticle technology. Once formulation conditions were optimized for the two initial combinations, the drug components could be “mixed and matched,” rapidly generating additional CombiPlex products with coordinated PK. This versatility was then taken one step further by generating a 3-drug combination, co-formulating selumetinib, AUY922 and docetaxel into a single hydrophobic prodrug nanoparticle.
The data have been accepted for presentation at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA November 5-9. Long ZKSS, CPXX -Ben
CAPN- http://globenewswire.com/news-release/2015/09/24/770688/10150427/en/Capnia-Announces-Publication-of-CoSense-R-Clinical-Data-in-the-Journal-Neonatology.html
IHUB Most read $TALK and Breakout board $TITXF #OTCBB https://t.co/gyA6Fii0v8
ARNI-I noticed this equity moved up 70% yesterday. I believe it was the result of 1/13/15 financing and subsequent Insider buying of appx 2.5M shares Best-Ben
EYEG-Wainwright PT $10
EYEG- http://www.eyegatepharma.com/investors/sec-filings/
Presentation: 01/19/2016 8-K Report of unscheduled material events or corporate event Current Reports DOC PDF
Cool! I found a trader thread. will keep my comments here.
Long 23K shares of ZFGN 6.55… feb 9 conf coming up. Usually I’d go alot bigger here (was looking for 75k shares) but I’ll keep it relatively small.
IMO longs from 12 have puked up most of their shares.
g
Essentially the trade rationale here is that the Feb 9 conf may be where they present the obesity data. Looking at how the stock reacted with the PWS data, the pps may react 30-50% on good obesity data. Judging by the prior p-values, IMO the p-value here will be around 0.001 or even better… plus when they announce the path forward (imo anticoagulation for PWS/belo?) I see a gap up.
g
ZFGN- Yeah! Thanks gamby1 🙂
CDNL- Penny 4 your thoughts? Best2You-Ben
Gambly….Great to have you here and loved the post….that is, minus the two numbers 23k and 75k. If Id bought 200, would the % success be any different?
Yes, because, tbh, when I know a trader is dealing with 200 shares, I have at least SOME idea of his or her account size. Trading 200 shares means that either A) you are a bad trader and hence 200 shares is alot for you… or B) you are wayyyyy too diversified.
IMO, knowing that someone is going into 200K$ trades or more either means that they have a decent sized account (and IMO they have the trading ability to get there)… or they just got a big inheritance and are going to lose it posthaste.
Also, when you are trading bigger blocks, you have to take into account the effect that it will have on the stocks you are trading. As a trader, looking at how blocks affect the stocks that you are trading is a huge informational help.
g
Gambly: I profoundly disagree…….poverty is no justification for being eliminated from the capitalist game or the market would be half the size….there are millions of small players, but in total they invest (ie affect the market) way more than some individual who goes 75k. Nor do I think that your ‘piddling’ 75k is gonna move the market….Its hardly Whale sized is it. Still, I will listen and learn. Just try to stop the defined quantities or explain why size matters trade by trade.
Thanks
Again… you are not a trader. From the way you post I can tell you have no idea how the mechanics of trading work… at least for micro or nano-cap bios work. Sure, you are right, 75k shares don’t matter when the mcap of a company is 1B$… but if you think that a 500K$ order isn’t going to affect the trading of a 30M$ mcap company, you are just showing your ignorance of _trading_
g
The market participants in microcap bios react to other trades… putting up a relatively big sell order can cause other traders to react to that and step in front of that order. It’s a huge consideration in these microcap bios.
There have been many situations in these microcap bios where I simply cannot get the position size I want, nor can I exit when I want to, without fading a move. It has essentially forced me to become a contrarian, which is fine.
Anyway. Good luck to both of us if we are in ZFGN. It’s a reasonable play here.
g
Agreed….75k on a 30mil stock CAN move the market….and if youre quick enough, you can profit from being quick on your feet. But you have more balls (or spare cash) than me….still Im learning.
I will say that I agree that Dr. KSS is right on… IMO belo will be approved in the end, and the PPS will hit 15-20$ this year. IMO.
So for those that are not traders, here is a decent entry in the mid 6’s. Will it go down to take out the 6$ stops again? maybe. Does that matter? not really. At this point, IMO, r/r is in favor of being long.
Being long at 12’s was crazy (after it had just spiked from 6) … and by extension, it was a bad idea not to sell at those levels.
Look, believe me, I do my DD as well. As a practicing MD (although not an MD-PhD like KSS) I can do my own DD and have been doing it on biotech stocks for 15 years (probably more than 40 hours per week).
I came to the realization that DD is not enough. You need to be able to judge sentiment and TRADE. People who do DD alone are missing a key component to be profitable, IMO. People who trade alone and don’t understand the difference between crispy lettuce and CRISPR are also at a disadvantage. Both techniques have their strengths, and, to completely ignore the other side is foolish, IMO.
g
Agreed
You could have bought in at any point after I bought at 16.24… where people sell is up to them. You don’t expect me to hold your hands and let you sell BEFORE me, do you?
I’d also add that buying ZFGN here at 6.55 is a heck of alot better than at 12, 11, 10, 9, 8, 7 etc…
and for those that didn’t sell at 12, well… that’s on them.
Now theres a statement of the obvious….. buy at the bottom….er wheres that Gambly?
We are very close to the bottom, IMO, at this 6.50’s level. Will this hit 5.5? Maybe… but in my mind, r/r is solid here. Note that this is not trading advice, this is just what I, PERSONALLY, believe. DYODD.
Agreed……I dont expect you to hold my hand….I just wanna be sure no one else does without realising that youre trading in real-time without providing anyone with a safety net.
Agreed. Trading is not for the faint of heart… but I believe that a good trader (and I have professional trader friends who are much better than me) can help find good entry points in stocks that one would (by “One” I mean a fundamental-ist) ALREADY INVEST IN from a fundamental standpoint.
g
$SUNE – SunEdison shares surge as review of financials finds no evidence of fraud
7:18 am ET (MarketWatch)
$SPEX- Good Morning! (no position)
Yesterday’s trade alert has so far confirmed our due diligence regarding what appears to be setting up as a classic bounce opportunity.
SPEX moved very quickly – which can possibly be attributed to the low float and high short interest setup. However, I believe the opportunity for upside is only beginning. As I mentioned in my due diligence yesterday, our belief is that the upside will play out over the coming few days based on the present chart setup. This looks very similar to my last trade alert, for those of you who recall and traded that successfully.
Based on reader feedback, as well as personally monitoring the trading activity, an average entry opportunity was presented around $2.20 and I am pleased to report that many of you didn’t chase and instead waited for the trade to come to you.
SPEX did have a very strong close on Thursday which confirms my belief that further upside opportunity is upon us, as I have mentioned earlier.
Intraday SPEX Chart – Closed Right Near Highs
Keep in mind that the float on SPEX is listed at under 2.5m shares while the short interest is listed at over 50%.
In addition to that, SPEX has just announced that they are going to be pursuing licensing agreements from a vast majority of their intellectual property. This is especially promising as we have seen in the past that “IP” companies can make enormous leaps in valuation based on favorable patent judgments or licensing agreements.
If you missed my initial report on SPEX you can find it here.
If you haven’t already, please reply to this email and let me know how your trade is going so far for you.
Happy Trading!
Track Record:
2014: 11 for +505%
2015: 32 for +296%
2016: 6 for +25%
January: 2 for +14%
February: 3 for +1%
March: 1 for +10%
SPEX- Our records indicate that xxxx requested and confirmed to be added to UltimateStockAlerts.com on xxxxxxxxxxx.
TRKK – P^D? Earthquake in Equador play on communications:
Good Morning!
Orbital Tracking Corp. (TRKK) earned the team a solid score about a month ago but I wonder now if that was just a taste of the real action.
TRKK satellite phones are in the spotlight now after new earthquakes in its key market of Japan and beyond. Here’s where their service SHINES!
And with TRKK showing up on billionaire venture capitalist Dr. Phillip Frost’s SEC radar, the rest of us have to fight a little harder for our shares.
Let’s see what that combination of shock catalyst and 5% of the float disappearing into billionaire hands does to the technical situation:
TRKK.png
Frost owns 5% of TRKK common and a vast chunk of the preferred. It’s just a tiny slice of his overall net worth, but it’s still a vote of confidence.
TRKK makes satellite phones and radio tag products, available all over the world from stores like Amazon and Alibaba.
The phones are pretty big in Japan due to disasters like the earthquakes going on now. Basically, when the normal grid fails, TRKK is in play.
Sales surged 63% to within a rounding error of $4 million last year, which is pretty impressive with TRKK down here at $0.08 — TRIPLE market cap.
Then there’s the tracking story. RFID is getting big buzz on Wall Street dream, so Frost’s interest in TRKK fits in with the Goldman Sachs POV.
Now compare all that chatter from high and low to the chart up there. We’re looking a little “oversold” on the RSI and other lines, aren’t we?
Every time TRKK let the RSI dip below 30, the action always bounced in fairly short order and traders earned 20% to 60%.
Of course the biggest bounces triggered when TRKK issued an update on its business: a big new product, quarterly numbers and so on.
Maybe we get that update soon in wake of what’s going on in key markets like Japan and now Ecuador feeling the shakes — watch the NEWS wire!
Even if we don’t, there’s a BILLIONAIRE already anted up on TRKK and the recent pressure on the chart looks unsustainable.
With Frost sitting on 5% of the float, who knows where the next bounce takes us? Today’s our first chance to find out! Sincerely, Michael Reef yourstockguy@gmail.com
$NNAB- The $CTIX younger generation boys equity:
NanoAntibiotics Acquires Company Developing Novel Therapies for Liver Disease
Announces New Company Name — BioVie, Inc.
BEVERLY, MA–(Marketwired – Apr 18, 2016) – NanoAntibiotics Inc. (OTC: NNAB) (the “Company”), a development stage company focused on the discovery, development, and commercialization of novel drug therapies, is pleased to announce the acquisition of LAT Pharma LLC, of Chicago, IL, an early-stage biotechnology company developing novel medicines to treat life-threatening complications of liver cirrhosis.
LAT Pharma brings a promising new therapeutic opportunity to NanoAntibiotics. Earlier this year LAT Pharma met with the FDA to discuss a submission for a novel therapy to treat ascites due to liver cirrhosis. The meeting designated as a “pre-investigational new drug (IND) meeting,” provided guidance that is currently being addressed. The Company’s goal is to commence a clinical trial program in human subjects upon FDA clearance of the IND application.
“The acquisition of LAT Pharma by NanoAntibiotics will provide the resources necessary to execute the next step in our goal of advancing a novel, potentially life-saving new drug therapy into the clinic,” commented Jonathan Adams, Chief Executive Officer at LAT Pharma.
In an all-stock, cashless deal, NanoAntibiotics acquired LAT Pharma LLC in a triangular merger in exchange for 39,820,000 newly-issued shares of the Company’s common stock. Following the retirement and cancellation of an equal number shares, the total number of NNAB shares outstanding post-merger will not change. Following the merger, the Company will change its name to BioVie, Inc.
About Liver Cirrhosis and Ascites
An estimated 1 million Americans and millions worldwide suffer from liver cirrhosis. Cirrhosis is the 12th leading cause of death due to disease in the US, killing an estimated 27,000 people each year. The condition results primarily from hepatitis, alcoholism, and fatty liver disease linked to obesity.
Ascites is a common complication of advanced liver cirrhosis. Approximately 60% of cirrhosis patients will develop ascites over a 10-year span. The prognosis for ascites is very poor, with an estimated 40% of patients dying within two years of diagnosis. Life-threatening complications of ascites include infection, sepsis, and circulatory dysfunction. Current treatments aim to provide symptomatic relief by eliminating fluids to reduce abdominal swelling. Certain medications may provide relief in the initial stages, but as the condition worsens, patients may fail to respond. US direct treatment costs for this condition are estimated at more than $4 billion annually.
About LAT Pharma LLC
LAT Pharma was founded with a mission to invent, develop, and commercialize therapies for people suffering from advanced liver cirrhosis and its life-threatening complications. The company’s initial disease target is ascites due to liver cirrhosis. Patients with ascites face a very poor prognosis and there are no effective drug therapies for the latter stages of this disease. Liver cirrhosis and related complications are the 12th leading cause of death due to disease in the US, killing an estimated 27,000 people each year. In addition to its pre-IND new drug candidate, the company has a collaboration with PharmaIN Corporation (Bothell, WA) to develop novel compounds for liver diseases.
Forward Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause NanoAntibiotics’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. NanoAntiobiotics has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are NanoAntibiotics’ need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact that NanoAntibiotics’ compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in NanoAntibiotics’ filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. NanoAntibiotics undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Antonio Costa @ACInvestorBlog 2h2 hours ago
Bio Stocks with great setups I’m watching today $CELG $BIIB $AMGN $TTPH $CMRX $AAVL $ADXS $OVAS $VRX $JUNO – Note: $IBB at breakout point
Ace @Super1NYC 1h1 hour ago
#Premarket Top % Gainers: $AMD 20%, $SKX 7%, $VRX 6%, $CXRX 3%, $UGAZ 3%, $HMY 2%, $DWTI $DUST $UNG $GILD $DB $ING $CRH $EDZ $SLV $JDST $SAP
#Premarket Top % Gainers: $AMD 29%, $PARN 17%, $NGL 11%, $PACB 9%, $CXRX 9%, $EBIO 7%, $SKX 7%, $VSLR $VRX $SHLD $GLBL $NSC $PFPT $SWN $XON
Ace @Super1NYC 6m6 minutes ago View translation
#Premarket Top % Gainers: $BP 4%, $DB 3%, $SAN 2% $MT $SDRL $HSBC $FCX $NXPI $CS $XIV $MU $CRH $SVXY $VRX $PHG $AMD $OPK $BHP $RIG $DNR $TNA
Ace @Super1NYC 14m14 minutes ago
#Premarket Top % Gainers: $DWA 23%, $EURN 10%, $STM 8%, $UWTI 6%, $UGAZ 4%, $UCO 3%, $SQQQ $SDRL $TVIX $CDE $UVXY $ERX $RIG $USO $ARMH $VXX
0 retweets 0 likes
GOGY, nada, consider the source do DD: Good Morning Ben & Welcome New Members,
Today, all eyes are on GOGY (Golden Grail Technology Corp) once again as it attempts to reach new heights!
If you missed GOGY yesterday, do NOT miss it today! Read yesterday’s Full Profile HERE.
Just this morning, GOGY even more BREAKING NEWS – this time regarding the expansion/rebranding of it’s swimwear client….
Golden Grail Announces Client New Strategy to Increase Sales
Cetoswim the Women’s Online Swimwear Shop Has Created SWIMandCOVER.com as Their Main Online Retailer to Gear up for the Spring/Summer Sales Season
DEERFIELD BEACH, FL–(Marketwired – April 27, 2016) – Golden Grail Technology Corp (GOGY), a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors, today is pleased to announce that one of its ongoing ecommerce clients, http://www.cetoswim.com/, a women’s online swimwear shop, has created SWIMandCOVER.com to be their main online shop. The new brand name presents a clearer message as to what the company is selling and will attract more customers. The company has also added a new collection for Spring/Summer 2016 and enhanced their online marketing to increase sales and traffic for this upcoming season. They will be keeping their original site Cetoswim.com as their discount online shop offering last year’s suits and resort wear. This tiered marketing strategy will allow for more traffic and capture shoppers at multiple price points. SWIMandCOVER.com is the main online retailer for the Swim by Chuck Handy swimwear line.
Swim by Chuck Handy was founded by Chuck Handy Jr., who draws from his extensive 35+ years’ experience in the swimwear industry to push the limits in material, manufacturing, style, price and designs. Unlike other brands, Swim by Chuck Handy swimsuits are sold as sets. Tankinis and one-piece swimsuits are available in sizes 8-24W and come with a coordinating cover-up. Each is constructed with pillow soft foam, molded cups and T3 Tummy Tamer Technology to ensure a flattering, comfortable fit. The company has offices in New Jersey, New York and Miami Beach.
“We are excited about Chuck Handy’s 2016 swimsuit line and the spring/summer selling season,” said Michael Brodsky, President of Golden Grail Technology.
Keep in mind that we are heading into the high season for as last May, GOGY announced RECORD SALES for the Month!
COULD GOGY CONTINUE IT’S MARCH UP?
Yesterday saw GOGY rally to highs of .055 – a 44% GAIN on the day – before closing at .435.
As noted, a break of .06 would be the sweet spot as it is a level that it has yet to break on three attempts this year.
However, while .06 has yet to be broken, GOGY did shatter another important resistance level @ .04 (as indicated first red dotted line).
With .04 now holding as support, could this just be the first step to a greater move?
Keep in mind, GOGY has a 52 Week High of .245.
A return to these levels give it up to 544% Upside Potential from here!
GOGY currently maintains a “STRONG BUY” Rating with 80% Opinion by Barchart.com!
WHO IS GOGY?
GOGY is a software tech solutions provider who’s mission is to use technology to accelerate small e-commerce businesses and give them opportunity to compete with industry giants. Through their e-commerce accelerating platform, GOGY gives companies the ability to enter digital markets quickly, economically and compete effectively with larger brands
With a flexible, revenue-share business model, the company can provide quick market entry and diversification with a low overhead – working to minimize risk and maximize investment return.
GOGY’s current portfolio of companies include BANDS OF VALOR memorial Jewelery, CETO SWIMWEAR/SWIMandCOVER swimsuit line, AIREOMATIC innovative fragrance air fresheners, and it’s newest line of Organic Health Foods, AH! Organic Brands which include the brands, Keenw-AH! quinoa, CheeAH! chia products, MacAH! maca products, and more!
THE BOTTOM LINE
With GOGY priming up for the high season and launching new e-commerce partners at a rapid pace, it appears the company has truly found a niche’ that works – and it’s resulting in significant Sales Growth!
With momentum on it’s side, there may be NO BETTER TIME to check out GOGY before it enters it’s high season!
Make sure you put it on your screen again RIGHT NOW and Follow on Twitter for all the Updates + Play-by-Play!
Good Trading,
Editor
StockoftheWeek.net
Antonio Costa @ACInvestorBlog 2m2 minutes ago View translation
Watch $ALQA $UNXL $VHC $MU for continuation.
Trading is a skill….no question about that. But its a lonely skill that cant be shared in real-time. The ins and outs are far too quick even for the internet. By the time a tip is published, the game will have changed. All that anyone can teach you are the signals/methods….after that, its up to you to employ them. Theres no such thing as a Traders tip….it will reverse in the flash of the eyelid.
By all means listen to stuff about the skill set….but DONT follow tips…..youll always be behind the 8 ball.
Been there, got the T shirt
Good. At least you acknowledge that trading is a skill. My point is that… just because people can’t trade themselves and rely on fundamental analysis… doesn’t mean that trading is impossible. The first rule of trading, IMO, is to acknowledge that I don’t care what your FA says… in the near-term, your FA will be over-ruled by sentiment and non-fundamental factors. In the end… maybe YEARS from now, FA will win. But that is if things don’t change by then. And things change often in biotech… so often that by the time you get years down the road, perhaps another competitor has emerged… or the technology is obsolete.
Essentially, it sounds like you are saying that there is no point in posting any of my trading ideas… because it can’t help anyone. I disagree. Buying ZFGN at 12 was, in retrospect, foolish. By my putting my nickel down here and saying that ZFGN at 6.55 is a decent buy, IMO… that helps people that already know that ZFGN is (IMO) a solid fundamental play… on this message board I think the fundamentals of ZFGN have been discussed enough that it is highly likely to be a good stock to invest in (IMO). The place where traders come in is… to decide WHEN to put your money on the line and buy ZFGN. I believe that, while this may not be the ABSOLUTE bottom, we are close enough, and have enough near-term catalysts, that buying here is likely a good decision. Note that this is not financial advice… and I am only legging in here with my ~23k shares… I’d probably buy another 50k shares in the low to mid 5’s, if it gets there.
g
I personally don’t understand why you are taking such offense to my posts… I have a feeling it is because you seem to believe that trading is impossible… and maybe you tried and failed… and now you seem to want to believe that if you can’t do it… then nobody can. I dunno… is anyone else here benefitting from my trading posts? if so, please let me know.
If my posts bother you so much, why do you even reply to them?
g
Open Outcrier (@OpenOutcrier) 3/17/16, 7:22 AM $AQXP (+24.1% pre) Baker Bros Advisors Raises Stake in Aquinox Pharmaceuticals (AQXP) to 45.1% ooc.bz/l/1120 no position
Gambly: Im not intending to reply ever more….. After 3yrs on SG, at least two of my posts to you have vanished. If thats the appreciation I get, Im outa here on all threads. I hope you give better value.
Alan, we love you and I know you have a strong desire to protect our community — that love doesn’t extend to ad hominem attacks and name calling directed toward other participants, which is why a couple of your posts (and the ensuing exchange) were removed. Sorry to hear that my censorship of name-calling implies a lack of appreciation, I hope you’ll stick around and continue your valued participation.
Gambly1 – Welcome to Stock Gumshoe!
I don’t have a problem with you posting your suggestions. I would even suggest you keep track of the recommendations you make here (buy/sell), date, shares, justifications, etc. Then we can all judge on the execution and performance of your picks.
However, I don’t care about your profits or losses, or drum beating. By that, I mean, I don’t see much value in multiple posts daily pushing your positions. Once a day, or change in your view, is sufficient.
There are multiple ways to trade. Not all of it is by what is called “fundamentals”. There is sentiment, momentum, technical, etc. Happy to listen to any points you have to make from your prespective.
I’ve cross-posted to “The arts and crafts of trading” and the “Biotech Traders thread” since it is now confusing EXACTLY where we should be posting.
EYES- (No position)
*Earlier 8-K from Second Sight Showed Slideshow for ’16 Investor Presentation; Showed $21.7M in Cash as of Sept. 30, 2015 with No Debt
8:21 am ET *UPDATE: Second Sight Says Study Results from Argus II Trial Program Will Be Presented at Annual Macula Society Meeting Feb. 24-27, 2016
Benzinga
8:00 am ET Second Sight to Announce Five-Year Data from Argus II Clinical Trial Program BusinessWire
Yesterday’s News, February 22, 20161:51 pm ET
Investors Look Into Second Sight Medical Products Inc After HBO Feature Is Announced
11:19 am ET Second Sight Pops 15%; HBO’s ‘Vice’ To Run Segment On ‘Beating Blindness’
11:15 am ET *Second Sight Spokesperson Confirms Approved Language, Copy Draft for ‘Vice’ Episode on ‘Beating Blindness’ Mentions Co.’s Argus II Product; However Co. Still Awaiting Final Release from HBO
Benzinga
May want to watch FUEL: (no position) Rocket Fuel Inc. is a technology company that has developed an artificial intelligence (AI) and big data-driven predictive modeling and automated decision-making platform. The Company’s technology is designed to address the needs of markets in which the volume and speed of information render real-time human analysis infeasible. It is focused on the digital advertising market that faces these challenges. The Company’s media-buying platform, which it refer to as its Demand-Side Platform (DSP) is available to advertising agencies and advertisers as a managed service offering, whereby it manages advertising campaigns on behalf of an advertiser, and through a self-service offering, whereby an agency or advertiser licenses its technology to manage its own advertising campaigns. Its AI system purchases ad spots, or impressions, one at a time, on these exchanges to create portfolios of impressions designed to optimize the goals of its advertisers.
Sogiam
Why is your post out of sync in the thread? Those before and after were posted Feb 5th?
wfuiii, when posts are deleted on a thread this cause the problem…perhapsT Travis or Lynn can straighten out idk Best2You-Ben
You sure? Just takes away from the post you put out on $FUEL….most won’t see it and I was hoping for others to discuss.
start a new discussion. upper part of the page.
Re-order-99.9% sure. Discuss away if you’d like. Subscribers to the thread hall receive message regardless. AI, the Cloud and VR is hot lately and shall be for many moons.
SUNE- (no position)
*UPDATE: SunEdison Says ‘We are gratified that the court denied the injunction and now we look ahead to continuing to navigate current market conditions.’
Benzinga
Premarket Top % Gainers: $LINE 15%, $CF 8%, $DGAZ 7%, $MOMO 7%, $SUNE 6%, $GASL 5%, $NUGT 5%, $HMY 4%, $GPL $NVDA $BBEP $AU $TVIX $UVXY $CHK
$LIFE volatility alert: Good Morning!
I hope you had a relaxing weekend.
I am emailing you this early morning update on my current trade opportunity – LIFE.
As we anticipated, LIFE experienced substantial volatility on Friday to both the upside and the downside and is currently holding onto the bullish trade setup we outlined in our initial due diligence. Nothing has changed.
Friday’s close, while reassuring of further upside opportunity, does suggest that there may be heightened volatility during the next few trading sessions. Our bias is still that there is a bullish case to be made as long as absolute support around $3.03 holds going further.
While the likelihood of downside is less than that of upside, it is important for me to emphasize that it is critical to monitor LIFE diligently.
If you have any other questions or comments please do reply to this email. I try to respond to every email that is sent to me.
——–
PLEASE NOTE: We are not making a judgment on LIFE as it relates to anything longer than a near-term trade opportunity.
LIFE carries the capability of being extremely volatile within a short amount of time. As such, these kinds of plays can be great for witnessing outsized gains but due to their volatile nature it is key to always use limit orders and avoid chasing if the stock moves away from you. If you do happen to miss your trading plans’ entry, do not panic. Waiting for dips in momentum stocks like LIFE during a trending market can be one of the best ways to approach the trade. We have tested this strategy before and it has been an overwhelming success on many occassion.
Happy Trading! UltimateStockAlerts Team